MedPath

Effect of Fruit Smoothie Supplementation on Psychological Distress Among People Receiving Opioid Agonist Therapy

Not Applicable
Active, not recruiting
Conditions
Substance-Related Disorders
Interventions
Dietary Supplement: Fruit smoothie
Registration Number
NCT05229770
Lead Sponsor
Haukeland University Hospital
Brief Summary

Background: People with substance use disorders generally have poor diets including limited intake of fruit and vegetables. Evidence shows substantial health benefits from increasing fruit and vegetable consumption on a variety of indicators and possibly also psychological distress. A pilot study has indicated that supplementation with fruit smoothie could be promising also among people receiving opioid agonist therapy (OAT) for opioid dependence. FruktBAR will compare the efficacy of fruit smoothie supplementation within the OAT clinics compared to standard treatment.

Study design: FruktBAR is a multicentre, randomised controlled trial. The trial will recruit approximately 230 patients receiving OAT in Bergen and Stavanger, Norway.

Intervention: The intervention involves daily supplementation with 250 ml fruit smoothie. The main endpoints are 16 weeks after intervention initiation. Participants will be included and followed up during and after intervention.

Study population: The target group will be patients with opioid dependence receiving OAT from involved outpatient clinics in Bergen and Stavanger.

Expected outcome: This study will inform on the relative advantages or disadvantages of a fruit supplementation in addition to the current medically and psychologically oriented treatment of people receiving opioid agonist therapy. If the supplementation is found to be safe and efficacious, it can be considered for further scale-up.

Detailed Description

See below each section

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
324
Inclusion Criteria
  • Receiving OAT from an included outpatient clinic with outpatient follow-up on weekly basis
  • Having fruit and vegetable intake below 3 portions per day (assessed at screening)
  • Confirming interest in participating in diet intervention (criteria specified)
  • Giving informed consent
Exclusion Criteria
  • Allergies or prior anaphylactic reactions involving fruits or vegetables
  • Poorly regulated diabetes type 1 or 2 (HbA1c >60 mmol/mol)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Fruit smoothieFruit smoothieParticipants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
Primary Outcome Measures
NameTimeMethod
Psychological distressMid of the intervention period 16 weeks after initiation

The primary outcome is psychological distress assessed with the Norwegian validated translation ten item version of Hopkins Symptom Checklist (SCL-10) in the mid of the intervention period 16 weeks after initiation (12-20). This will be evaluated with mean SCL-10 item score and compared between intervention and control arm.

Secondary Outcome Measures
NameTimeMethod
Biochemical indicators of fruit intakeMid of the intervention period 16 weeks after initiation

Biochemical indicators of fruit intake measured with serum carotenoids

Fatigue Symptom ScaleMid of the intervention period 16 weeks after initiation

Changes in fatigue will be assessed with the Fatigue Symptom Scale (FSS-3, scale 0-18, higher values is worse)

Biochemical indicator of inflammationMid of the intervention period 16 weeks after initiation

Biochemical indicators of inflammation measured with C-reactive protein in serum

Physical functioningMid of the intervention period 16 weeks after initiation

Physical functioning assessed with 4-minute step-test measuring number of steps climbed in period

Health-related quality of lifeMid of the intervention period 16 weeks after initiation

Changes in health-related quality of life will be assessed with EuroQoL EQ-5D-5L (0-100, higher is better)

Trial Locations

Locations (2)

LAR Helse Stavanger HF

🇳🇴

Stavanger, Rogaland, Norway

Department of Addiction Medicine, Haukeland University Hospital

🇳🇴

Bergen, Vestland, Norway

© Copyright 2025. All Rights Reserved by MedPath